Kyntra Bio (KYNB) Net Cash Flow (2014 - 2026)
Kyntra Bio (KYNB) posted Net Cash Flow of -$10.9 million for Q1 2026, up 84.47% sequentially from -$70.1 million in Q4 2025, and down 515.91% YoY from $2.6 million in Q1 2025.
Kyntra Bio (KYNB) Net Cash Flow (2014 - 2026) Analysis & Trends
Kyntra Bio has reported Net Cash Flow for 13 years, with the latest figure at -$10.9 million in Q1 2026.
- Quarterly Net Cash Flow fell 515.91% year-over-year to -$10.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$68.9 million (down 4588.5% YoY) and the FY2025 annual result came in at -$55.4 million, down 351.7% from the prior year.
- Net Cash Flow climbed to -$10.9 million in Q1 2026 per KYNB's latest filing, from -$70.1 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $33.4 million in Q1 2023 and troughed at -$70.1 million in Q4 2025.
- A 5-year average of -$7.5 million and a median of -$8.2 million in 2024 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2024 and 2026: Net Cash Flow jumped 197.23% in 2024, then tumbled 515.91% in 2026.
- Over 5 years, Net Cash Flow stood at -$2.7 million in 2022, then slumped by 203.17% to -$8.3 million in 2023, then slumped by 245.2% to -$28.7 million in 2024, then slumped by 143.77% to -$70.1 million in 2025, then surged by 84.47% to -$10.9 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$10.9 million, -$70.1 million, and -$604000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Kyntra Bio | 30.42 Mn | 30.42 Mn | 1.47 Mn | 13.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.68 Mn |
| Jun 30, 2026 | 13.68 Mn |
| Mar 31, 2026 | -10.88 Mn |
| Mar 31, 2026 | -10.88 Mn |
| Dec 31, 2025 | -70.05 Mn |
| Dec 31, 2025 | -70.05 Mn |
| Sep 30, 2025 | -604,000.00 |
| Sep 30, 2025 | -604,000.00 |
| Jun 30, 2025 | 12.66 Mn |
| Jun 30, 2025 | 12.66 Mn |
| Mar 31, 2025 | 2.62 Mn |
| Mar 31, 2025 | 2.62 Mn |
| Dec 31, 2024 | -28.74 Mn |
| Dec 31, 2024 | -28.74 Mn |
| Sep 30, 2024 | -7.75 Mn |
| Sep 30, 2024 | -7.75 Mn |
| Jun 30, 2024 | 32.40 Mn |
| Jun 30, 2024 | 32.40 Mn |
| Mar 31, 2024 | -8.18 Mn |
| Mar 31, 2024 | -8.18 Mn |